|
|
|
Soleno Therapeutics Inc (NASDAQ: SLNO) |
|
Soleno Therapeutics Inc
Officers & Directors
ANDREW SINCLAIR Director BIRGITTE VOLCK Director MATTHEW PAULS Director GWEN MELINCOFF Director ERNEST MARIO Chairman JAMES MACKANESS Chief Financial Officer (Principal Financial and Accounting Officer) WILLIAM G. HARRIS Director ANISH BHATNAGAR President, Chief Executive Officer and Director (Principal Executive Officer) MARUM LLP ...,
Soleno Therapeutics Inc currently has 182 employees.
News about Soleno Therapeutics Inc Key Personnel |
Soleno Therapeutics Public Offering Raises Questions Amidst Financial Struggles
Soleno Therapeutics, a leading clinical-stage biopharmaceutical company focused on rare disease therapeutics, has recently undergone significant changes in its leadership and financial landscape. The resignation of Ernest Mario, Ph.D., as the Chair of the Board of Directors due to health reasons, and the appointment of Matthew Pauls, J.D., M.B.A., as the new Lead Independent Director, has sparked curiosity among investors and industry insiders. These developments coincide with Soleno Therapeutics recent announcement of its underwritten public offering, which aims to bolster the company s financial position.
However, t...
|
Soleno Therapeutics Submits New Drug Application for DCCR Tablets to Treat Prader-Willi Syndrome
The pharmaceutical industry is constantly striving to develop innovative treatments for rare diseases, and Soleno Therapeutics is one company at the forefront of this mission. Soleno Therapeutics, a clinical-stage biopharmaceutical company, recently announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of DCCR (diazoxide choline) extended-release tablets. This novel treatment is intended specifically for individuals aged four years and older who suffer from Prader-Willi syndrome (PWS) and experience hyperphagia, a condition that causes exces...
|
Soleno Therapeutics, a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics for rare diseases, has recently made significant appointments to its leadership team. These strategic additions, along with the engagement of esteemed advisors, reflect the company s commitment to enhancing its commercial operations, expanding into European markets, and optimizing its human resources. With these new developments, Soleno Therapeutics aims to propel its growth trajectory and deliver novel treatments to patients in need.
Appointments to the Leadership Team:
Soleno Therapeutics has appointed Meredith Manning, M.B.A., as its Chief Commercial Officer, leveraging her ...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
